Meet the editor

Hamid Elia Daaboul, MD, PhD is an ASCO active member and researcher in the mode of action of new potential anticancer molecules in the Lebanese American University, Lebanon. He is a practicing Oncologist and also a former Head of Department of Oncology in Haroun Hospital, Lebanon. He earned his PhD in Oncology from Surrey University, London. He studied the mode of action of β-2-himachalen-6-ol, a new anticancer molecule,

and succeeded in identifying its apoptotic effect via the inhibition of the mitogen-activated protein kinases (MAPK/ERK) and the phosphatidylinositol 3-kinase (PI3K/AKT) cellular signalling pathways. He is also engaged in clinical trials of other potentially active anticancer molecules.

## Contents


